Member Info for Parob

We’ve completed a human study on our patented, natural, low calorie alternatives to sugar, SweetBiotix®! If your'e visiting Probiota, make sure you visit the Scientific Frontiers session to read more about the study. http://ow.ly/7j8z30nEDoG “Whilst our previous studies have demonstrated that these fibres have high sweetness and no aftertaste, this is the FIRST STUDY TO OUR KNOWLEDGE of a high intensity sweetener demonstrating a positive effect on the microbiome.”

hTTps://lemminginvestors.blogspot.com/2019/02/optibiotix-health-yet-another-lp-ldl.html Recent, current and potential future revenue streams confirmed: - GoFigure: shakes, bars and muesli pots - CholBiome (x3 and Daily Maintenance) - Sacco/CSL - HLH BioPharma Vertriebs GmbH - Nutrilinia (LD-LDL and Slimbiome Medical) - Pharmabiota - Galenicum Special Ingredients - Knighton Foods - Cereal Ingredients Inc. - Fine Foods & Pharmaceuticals - Trigen Pharma - Cambridge Commodities - Akums Drugs and Pharma - Seed Health - John Morley’s - Alfasigma - Unnamed global corporate ($100B+ turnover) for SweetBiotix manufacturing & distribution. - Unnamed US pharma partner (cholesterol strain) - Bened Biomedical - Bulgarian CholBiome distributor (Velinoff Pharma) - CTC Group - Formulation Creations - US Pharma Lab Inc. - Unnamed Greece and Cyprus CholBiome distributor - Unnamed Greece and Cyprus SlimBiome Medical distributor - Zeon Lifesciences - SilvExpo - CholBiome - Biolat - RMS CardioPro Revenue not confirmed yet: - Tata X 2 (Slimbiome and LPGOS) - Mystery US Slimbiome customer - Paradise Fruits (Slimbiome) - Beijing Duoite Biotechnology Co., Ltd (LP-LDL distributors via CSL) Products on the market already but not RNSed: - MuscleForm (Aviform Ltd) - Ultra MR Ultimate Meal Replacement - Olliscience - Ollibiotic - Aragan - Biotic•P3 - 39ytu - Capsa Food

New Spanish partner discovery by AJS! Contains Lactobacillus Plantarum LP LDL Product on sale here: https://www.39ytu.com/soluciones-bioactivas/3/Reducir-tu-colesterol Link to brochure: https://www.39ytu.com/assets/resources/3/reduce-colesterol.pdf Capsa food behind it: https://www.capsafood.com/39ytu-precision-nutrition-from-your-microbiota/

Join here: https://groups.google.com/forum/m/#!forum/lemminginvestors A fund manager with 30 years in the city who is a member recently commented: “this Forum is gold plated, and an absolute must for quality research that provides brilliant information on understanding the business model”

Four AIM shares on the cusp of something big by Andrew Hore from interactive investor | 18th January 2019 15:24 https://www.ii.co.uk/analysis-commentary/four-aim-shares-cusp-something-big-ii507543? This former AIM writer of the year names the small-caps that could be about to fulfil their potential.

https://tinyurl.com/ybrwbxpn
 
(Interview ?starts at 23? minutes 58 seconds)
 
Hayden Locke, Chief Executive Officer of Emmerson (EML) talks through some of the key work streams and newsflow expected for the company in 2019.
Emmerson's primary focus is on developing the Khemisset Potash Project located in Northern Morocco. The project has a large JORC Resource Estimate (2012) of 311.4Mt @ 10.2% K2O and significant exploration potential with an accelerated development pathway targeting a low capex, high margin mine. Khemisset is perfectly located to capitalise on the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. This unique positioning means the project will receive a premium netback price compared to existing potash producers. The need to feed the world's rapidly increasing population is driving demand for potash and Emmerson is well placed to benefit from the opportunities this presents.
 

Bullish pennant forming on the chart. Once that breaks we’re looking at 130p+ pretty quickly imo.

New SOH Interview just out OptiBiotix’s SlimBiome gathers steam as subsidiary eyes potential IPO 15:52 07 Jan 2019 Life sciences firm OptiBiotix Health plc (LON:OPTI) has clinched a number of deals for its SlimBiome weight loss product as the company eyes up a potential initial public offering (IPO). Founder and CEO Stephen O'Hara tells Proactive London how OptiBiotix is changing from an R&D company to a business with greater commercial focus with a number of new deals in 2019 and our prodcuts migrating into other territories. The group has just inked an agreement with Indian firm Zeon Lifesciences Ltd, granting it an exclusive licence to manufacture and supply SlimBiome in the return in return for a 50% share of the profits. https://tinyurl.com/yano3ttb

https://en.wikipedia.org/wiki/Obesity_in_India Obesity in India has reached epidemic proportions in the 21st century, with morbid obesity affecting 5% of the country's population.[1] India is following a trend of other developing countries that are steadily becoming more obese. Unhealthy, processed food has become much more accessible following India's continued integration in global food markets. This, combined with rising middle class incomes, is increasing the average caloric intake per individual among the middle class and above income households.[2] Obesity is a major risk factor for cardiovascular disease, NGOs such as the Indian Heart Association have been raising awareness about this issue.[3]

Guys, if you haven’t already, it’s worth checking out risky’s post (44998) over on the advfn board for an in-depth explanation of OPTI’s b2b business model. More good news must be due very soon, which will hopefully blast us through £1, then we can look forward to reaching new all time highs as the market catches up and realises what we have developing here.

Galenicum started promoting ‘Stop&Go Colesterol’ on their own website today as they officially launch the supplement. It’s the first product listed on their ‘Products’ page: hTTps://www.stopandgogalenicum.com/productos/ More detailed info on the product here: https://www.stopandgogalenicum.com/productos/colesterol/

A series of Ed McDermott tweets (@edmcdermott12) from the 4th Dec - share price was 3p at the time:

#EML while I’m very disappointed with the current share price, I am pleased with the speed and precision of the operational development. Our scoping study is superb and we are well funded till 2020. #Potash

It has been anti-climatic and I think it comes down to investors believing that future capex requirements are going to require big equity placings. A project of this scale with this level of IRR it’s a very good fit for banks to project finance.

EML funded into early 2020 which Hayden has stated in interviews and RNS. The team achieved project financing for Highfield on a lower IRR (at the time). I have confidence Khemisset is a very financeable project and of national importance in Morocco.

Hayden is an exceptional CEO, I believe his knowledge of the Potash market is second to none. He is not short of job offers and wouldn’t be running EML if he didn’t believe it was significant. This is not advice or recommendation to buy, hold, sell etc. Always do research.

Re future items there are many to look forward to. I can’t discuss specifics but the Scoping study is just the beginning of development. Potash is a favourite of a number of major miners, Potash miners achieve similar ratings to chemical co multiples

By Elrico: https://lemminginvestors.blogspot.com/2018/12/optibiotix-health-chat-with-ceo-stephen_19.html

https://lemminginvestors.blogspot.com/2018/12/optibiotix-health-chat-with-ceo-stephen.html

Millions have already been wiped off but OPTI has been rising over the last few weeks (almost 50%) and momentum is there to take it much higher, especially with the deal-flow that’s anticipated. Cream always rises to the top and exponential growth stocks (with pretty static operational costs) could benefit as safe havens whilst other stocks fall. I’ve sold some losers to put more in here recently.

Latest blog by Elrico: https://lemminginvestors.blogspot.com/2018/12/optibiotix-health-probiotix-strategic.html

So the new partner discovery this week was Beijing Duoite Biotechnology Co Ltd based in China, promoting LP-LDL (through CSL) on their website: http://www.bjdoit.com/index.php?m=content&c=index&a=lists&catid=34 I’ve added to the list to keep track! Current and future revenue streams confirmed so far: - GoFigure: shakes, bars and muesli pots - CholBiome (x3 and Daily Maintenance) - Sacco/CSL - HLH BioPharma Vertriebs GmbH - Nutrilinia (LD-LDL and Slimbiome Medical) - Pharmabiota - Galenicum Special Ingredients - Knighton Foods - Cereal Ingredients Inc. - Fine Foods & Pharmaceuticals - Trigen Pharma - Cambridge Commodities - Akums Drugs and Pharma - Seed Health - John Morley’s - Alfasigma - Unnamed global corporate ($100B+ turnover) for SweetBiotix manufacturing & distribution. - Unnamed US pharma partner (cholesterol strain) - Bened Biomedical - Bulgarian CholBiome distributor (thought to be Velinoff Pharma) - CTC Group - Formulation Creations - US Pharma Lab Inc. - Unnamed Greece and Cyprus CholBiome distributor - Unnamed Greece and Cyprus SlimBiome Medical distributor Revenue not confirmed yet: - Tata X 2 (Slimbiome and LPGOS) - Mystery US Slimbiome customer - Paradise Fruits (Slimbiome) - Beijing Duoite Biotechnology Co., Ltd (LP-LDL distributors via CSL) Products on the market (already or soon) but not RNSed: - MuscleForm (Aviform Ltd) - Ultra MR Ultimate Meal Replacement - Olliscience - Ollibiotic - SilvExpo - RSM CardioPro and CholBiome - Aragan - Biotic•P3

Anyone who has followed the story closely will know that the revenues SOH refers to will be from both recurring and non-recurring streams – non-recurring ones are all highlighted in the RNS over the past year (US pharma, Sweetbiotix global corporate partner, Akums etc)

Excellent post Trek. Have copied and pasted on the advfn board. Hope you don’t mind! Just 19p to go until we’re back at a £100M market cap. I’m sure last Tuesday’s game changing RNS perked the interest of a few new institutions. Hitting a £100M MC will increase that interest.

The three stocks that are 'Brexit proof' – why these small firms are immune from the gathering storm https://uk.finance.yahoo.com/news/three-stocks-brexit-proof-small-firms-relatively-immune-gathering-storm-154254169.html